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Introduction
Verrucous hemangiomas (VH) are hyperkeratotic vascular
malformations characterized by a combination of dilated
vasculature in the entire dermis, or even much deeper, and
prominent hyperkeratosis, which may result in papules,
patches, or violet-colored erythematous tumors. Bleeding
after trauma or scratching is frequent. Surgery is nowadays
the gold-standard treatment but laser therapymay nevertheless
be useful in the superficial component of the lesions. Treat-
ments with argon laser and copper vapor laser have been used
[1], but both are limited by lack of specificity, poor
penetration, and adverse sequelae. Recently, the Nd:YAG
1,064-nm laser has been used in a few cases, either alone or
combined with CO2 or the pulsed dye laser (PDL) [2].
Materials and methods
We report our experience as a tertiary referral hospital laser
unit in the treatment of VH with different combinations of
laser therapy over the last 10 years: CO2 laser (10–30 W
continuous-wave mode), PDL 595 nm (7 mm, 2 ms, 10–
12 J/cm2) and combined dual PDL-Nd:YAG (Cynergy with
Multiplex™, Cynosure, Westford, MA) (PDL: 7 mm, 10 ms,
10 J/cm 2 with 1-s delay and Nd:YAG: 15 ms, 50–100 J/
cm2). Continuous airflow cooling (Cryo5s, Zimmer Medi-
zinsysteme GmbH, Neu-Ulm, Germany) was always applied
at its maximum level (6) during laser treatment.
Post-laser care consisted of the daily application of
topical antibiotic ointment (Fucidine©) until spontaneous
detachment of the scab. Strict avoidance of sun exposure of
the treated areas was recommended for at least 2 months to
avoid postinflammatory hyperpigmentation.
The study period included eight patients (seven female
and one male) evaluated for laser treatment of VH. The
mean age of the patients was 6.5 years (range: 3–
16 years). All the patients presented multiple hyperkera-
totic erythematous plaques that had developed in early
childhood, located on the lower limbs, except for one on
the left forearm (patient number 7). The lesions were
heterogeneous with hyperkeratotic areas interspersed with
flat incipient vascular lesions with no hyperkeratosis, all
representing a challenge in terms of surgical treatment.
Biopsies confirmed the diagnosis of VH.
None of the patients had any relevant personal or family
history and no muscle or bone involvement was noted with
magnetic resonance imaging. All the patients underwent
laser treatment under local anesthesia, except for one girl
who required general anesthesia. Two dermatologists
evaluated the effectiveness of the treatment by means of
photographs of the patients before and after the therapy.
Ulceration, infection, scarring, atrophy, hypopigmentation,
hyperpigmentation, or other side-effects were recorded.
Patient satisfaction, or parent satisfaction if the patient was
a minor, was rated on a scale from 0 to 10.
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Results
The best response in the hyperkeratotic superficial portion
was obtained with CO2 laser, but the superficial and deep
vascular components responded better to dual PDL-Nd:
YAG laser (Figs. 1–4). PDL was only useful in very
superficial lesions to prevent the development of the early
hyperkeratotic component of some of these lesions [3].
Ulceration, scarring, and hypopigmentation can appear but
most of the lesions improved markedly, resulting in a better
quality of life. No infectious problems were seen in our
patients (Table 1).
Discussion
In 1967, Imperial and Helwig introduced the term “verru-
cous hemangioma”, and defined it as a congenital vascular
malformation comprising a capillary or cavernous heman-
gioma in the dermis and subcutaneous tissue associated
with reactive epidermal acanthosis, papillomatosis, and
hyperkeratosis, distinguishing it from angiokeratoma [4].
Currently, most authors consider VH to be a malformation
of dermal capillaries and encourage use of the term
hyperkeratotic vascular malformation to describe this type
of vascular change [5]. Nonetheless, the histopathological
features and the reactivity against specific immunohisto-
chemical markers (focal GLUT-1 endothelial positivity)
have led other authors to be cautious about encompassing
VH in the group of vascular malformations or tumors [6].
Given the clinical course of these lesions, we prefer the
term hyperkeratotic vascular malformation.
The lesions are generally noted at birth or in early
childhood [7], although they may appear later or even in
adult life. Most VH are multiple lesions and are located on
the lower extremities, with unilateral involvement [8]. The
Fig. 1 a Verrucous hemangioma on the lower limb of a 4-year-old
girl. b Improvement after sessions with PDL and combined dual PDL-
Nd:YAG laser
Fig. 2 a Verrucous hemangioma on the lower limb of a 16-year-old
male. b Improvement after sessions with CO2, PDL and combined
dual PDL-Nd:YAG laser
Fig. 3 a Verrucous hemangioma on the lower limb of a 4-year-old
girl. b Improvement after sessions with CO2, PDL and combined dual
PDL-Nd:YAG laser
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early clinical lesions are nonkeratotic, soft, and bluish-red
in color, but in time they become increasingly hyperkera-
totic and verrucous, usually following trauma or infection
[6, 8–10].
The differential diagnosis of VH includes angiokera-
toma, lymphangioma circumscriptum, angioma serpigino-
sum, verrucous epidermal naevus, verrucous cancer, or
even malignant melanoma [6–8, 10, 11]. Occasional venous
malformations may also mimic VH, though there is usually
minimal hyperkeratosis [9].
Diagnostic histopathological findings are ectatic vessels
underlying an acanthotic and hyperkeratotic epidermis in
combination with deeply localized vascular formations
interspersed with fatty tissue [12]. Inflammatory cells,
hemosiderin, and fibrosis may be present in the upper
dermis [7]. VH resemble angiokeratoma, although VH
involve small, thick-walled, blood-filled vessels with a
multilamellated basement membrane involving the dermis
as well as fatty tissue [6, 9].
VH do not resolve spontaneously, and have a tendency
to relapse. Early diagnosis and treatment is important to
achieve a better cosmetic result [8]. Management of VH
has included excision, cautery, cryosurgery, and laser
therapy [11, 13]. VH require a large, deep excision because
they extend into the subcutis, occasionally involving the
fascia. Incomplete extirpation can lead to recurrence [8,
9, 11, 14]. Yang and Ohara performed surgery in
combination with PDL, CO2 laser, or argon laser in 23
patients with VH and reported that a combination
approach using surgical reconstruction and laser is
necessary for large and extensive lesions [15]. Surgery is
even more complicated due to the multiplicity of lesions in
the same patient. Although laser treatment is only
palliative, it cannot treat the deep component, and requires
Fig. 4 a Verrucous hemangioma on the lower limb of a 7-year-old
girl. b Improvement after sessions with PDL and combined dual PDL-
Nd:YAG laser
Table 1 Clinical characteristics, outcome, and laser used in the treatment sessions
Patient
no.
Age
(years)
Gender Extension Hyperkeratotic
component –
Treatment with
CO2 laser*
Superficial
vascular
component –
Treatment with
PDL
Deep vascular
component –
Treatment with
Dual PDL-Nd:
YAG
Number
of
sessions
Response** Degree of
satisfaction***
1 7 Female 30 cm2 +++ + + >10 +++ 9
2 16 Male 40 cm2 +++ + + >10 ++++ 10
3 6 Female 30 cm2 + + + 1-5 ++ 10
4 7 Female 15 cm2 + + + 5-10 +++ 8
5 11 Female 40 cm2 ++ + + >10 +++ 8
6 4 Female 25 cm2 +++ + + >10 +++ 8
7 5 Female 20 cm2 + + + >10 +++ 10
8 3 Female 25 cm2 + + + 1-5 ++++ 9
* Hyperkeratotic component – (treated with CO2 laser for patients with 2–3 passes):
+ Hyperkeratosis<2 mm
++ Hyperkeratosis 2–4 mm
+++ Hyperkeratosis>4 mm
** Response: 0–25% (+), 25–50% (++), 50–75% (+++), 75–100% (++++)
*** Degree of satisfaction: from 1 (poor) to 10 (excellent), valued by the patient or a parent if a minor
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multiple treatment sessions, as in our patients. It is
nevertheless worth using in many patients in an attempt
to avoid surgery.
Finally, a recent study reported that hypertrophic and
PDL-resistant port-wine stains showed improvement with a
755-nm alexandrite laser, which should also be considered
in the future as a new therapeutic option for verrucous
hemangioma [16, 17].
Conclusions
Treatment of VH can be difficult and recurrence is
common. Surgery should always be considered for these
patients, though laser treatment should be tried beforehand,
even though it is only palliative. We have observed a very
satisfactory response to laser treatment in some circum-
scribed lesions and partial response of the superficial
component of deeper lesions, with an improvement in
quality of life and patient satisfaction. Thus, combined laser
therapy (CO2 and dual PDL-Nd:YAG laser) may be useful
in most cases of verrucous hemangiomas.
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